GeneDx Financial Ratios
NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GeneDx ratio analysis
GeneDx earned a net margin of -4.9% in FY 2025, up from -17.1% a year earlier. Gross margin was 69.7% compared with a median of 22.2% over the prior 6 years. Return on equity reached -6.8%, meaning GeneDx generated -0.07 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.17 versus 0.22 the year before, and the current ratio was 2.46. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
GeneDx financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / sales | 8.86 | 6.97 | 0.33 | 0.38 | 74.96 | 0.01 | — |
| Price / book | 12.30 | 8.68 | 0.29 | 0.35 | 40.99 | — | — |
| Gross margin | 69.7% | 63.6% | 44.4% | -11.4% | -7.8% | 2.2% | 42.2% |
| Operating margin | -3.1% | -7.6% | -89.2% | -284.5% | -210.3% | -134.9% | -15.5% |
| Net margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | -134.6% | -15.1% |
| Free cash flow margin | 3.3% | -11.1% | -91.5% | -139.0% | -94.2% | -65.4% | -15.6% |
| Return on equity (ROE) | -6.8% | -21.3% | -77.1% | -216.4% | -63.2% | — | — |
| Return on assets (ROA) | -4.0% | -12.5% | -42.0% | -111.8% | -44.3% | -95.9% | — |
| Debt / equity | 0.17 | 0.22 | 0.23 | 0.04 | 0.03 | — | — |
| Current ratio | 2.46 | 3.61 | 3.10 | 1.47 | 4.77 | 2.37 | — |
| Revenue growth | 40.0% | 50.8% | -13.7% | 10.6% | 18.3% | -8.6% | — |